Once-Daily Extended-Release Versus Twice-Daily Standard-Release Tacrolimus in Kidney Transplant Recipients: A Systematic Review
BACKGROUNDA simplified dosing regimen may improve drug compliance in kidney transplant recipients and long-term graft outcomes. We aimed to identify, appraise, and synthesize the current evidence comparing the relative safety and efficacy of the recently introduced daily versus standard twice-daily...
Gespeichert in:
| Veröffentlicht in: | Transplantation 2013-05, Vol.95 (9), p.1120-1128 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1128 |
|---|---|
| container_issue | 9 |
| container_start_page | 1120 |
| container_title | Transplantation |
| container_volume | 95 |
| creator | Ho, Elaine T.L Wong, Germaine Craig, Jonathan C Chapman, Jeremy R |
| description | BACKGROUNDA simplified dosing regimen may improve drug compliance in kidney transplant recipients and long-term graft outcomes. We aimed to identify, appraise, and synthesize the current evidence comparing the relative safety and efficacy of the recently introduced daily versus standard twice-daily tacrolimus administration.
METHODSWe systematically reviewed all randomized controlled trials and observational studies that compared the outcomes of daily versus twice-daily tacrolimus formulation in kidney transplant recipients. Medline (from 1948 to July week 4 2011), Embase (1980 to 2011 week 31), the Cochrane Library (1991 to June 2011), and conference proceedings were searched without language restriction.
RESULTSSix randomized controlled trials (n=2499) and 15 observational studies (n=2886) were included in the review. There were no significant differences in biopsy-proven acute rejection (two trials, n=1093; risk ratio [RR; confidence interval (CI)], 1.24 [0.93–1.65]; P=0.15; I=0%), patient survival (three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.55; I=32%), and graft survival (three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.67; I=0%) between the two formulations at 12 months. Similar results for acute rejection (five studies, n=391; RR [CI], 0.99 [0.93–1.06]; P=0.84; I=0%) and overall patient survival (two studies, n=218; RR [CI], 1.02 [0.94–1.10]; P=0.62; I=0%) were observed in observational studies.
CONCLUSIONSOnce-daily tacrolimus appears to be as effective as twice-daily tacrolimus up to 12 months after kidney transplantation. |
| doi_str_mv | 10.1097/TP.0b013e318284c15b |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1443369956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1443369956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336b-1349684f24555bd6cdcd6782b8fa4005d454113517d9e9bc0ea50810ddb3f9f63</originalsourceid><addsrcrecordid>eNqN0UtPxCAQB3BiNLo-PoGJ6dFLFQqU1pvR9RFNNFq9NhSmEaXdFajrnvzqYtZH4sF44sBvZhj-CG0TvEdwKfar6z3cYEKBkiIrmCK8WUIjwilLc1zgZTTCmJGUUCrW0Lr3jxhjToVYRWsZ5SxjeTlCb1e9gvRYGjtPxq8Beg06vQEL0kNyD84PPqlm5tvcBtlr6X5MJZWbWNNFZ_rkwuge5knlZO-nVvYhuQFlpgb64A-Sw-R27gN0MhgVL14MzDbRSiuth63PcwPdnYyro7P08ur0_OjwMlWU5k1cgpV5wdqMcc4bnSutdC6KrClayeJamnFGCOVE6BLKRmGQHBcEa93QtmxzuoF2F32nbvI8gA91Z7wCG98Ik8HXhLE4qCz5PygVOI-Yi0jpgsY_8N5BW0-d6aSb1wTXHyHV1XX9O6RYtfM5YGg60N81X6lEIBZgNrEhZvBkhxm4-gGkDQ9_tn4HMQWgOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1370633657</pqid></control><display><type>article</type><title>Once-Daily Extended-Release Versus Twice-Daily Standard-Release Tacrolimus in Kidney Transplant Recipients: A Systematic Review</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Ho, Elaine T.L ; Wong, Germaine ; Craig, Jonathan C ; Chapman, Jeremy R</creator><creatorcontrib>Ho, Elaine T.L ; Wong, Germaine ; Craig, Jonathan C ; Chapman, Jeremy R</creatorcontrib><description>BACKGROUNDA simplified dosing regimen may improve drug compliance in kidney transplant recipients and long-term graft outcomes. We aimed to identify, appraise, and synthesize the current evidence comparing the relative safety and efficacy of the recently introduced daily versus standard twice-daily tacrolimus administration.
METHODSWe systematically reviewed all randomized controlled trials and observational studies that compared the outcomes of daily versus twice-daily tacrolimus formulation in kidney transplant recipients. Medline (from 1948 to July week 4 2011), Embase (1980 to 2011 week 31), the Cochrane Library (1991 to June 2011), and conference proceedings were searched without language restriction.
RESULTSSix randomized controlled trials (n=2499) and 15 observational studies (n=2886) were included in the review. There were no significant differences in biopsy-proven acute rejection (two trials, n=1093; risk ratio [RR; confidence interval (CI)], 1.24 [0.93–1.65]; P=0.15; I=0%), patient survival (three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.55; I=32%), and graft survival (three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.67; I=0%) between the two formulations at 12 months. Similar results for acute rejection (five studies, n=391; RR [CI], 0.99 [0.93–1.06]; P=0.84; I=0%) and overall patient survival (two studies, n=218; RR [CI], 1.02 [0.94–1.10]; P=0.62; I=0%) were observed in observational studies.
CONCLUSIONSOnce-daily tacrolimus appears to be as effective as twice-daily tacrolimus up to 12 months after kidney transplantation.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/TP.0b013e318284c15b</identifier><identifier>PMID: 23542469</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Bacterial Infections - epidemiology ; Drug Administration Schedule ; Graft Rejection ; Graft Survival ; Humans ; Immunosuppressive Agents - administration & dosage ; Kidney Transplantation - mortality ; Randomized Controlled Trials as Topic ; Tacrolimus - administration & dosage ; Tacrolimus - pharmacokinetics</subject><ispartof>Transplantation, 2013-05, Vol.95 (9), p.1120-1128</ispartof><rights>2013 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c336b-1349684f24555bd6cdcd6782b8fa4005d454113517d9e9bc0ea50810ddb3f9f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23542469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ho, Elaine T.L</creatorcontrib><creatorcontrib>Wong, Germaine</creatorcontrib><creatorcontrib>Craig, Jonathan C</creatorcontrib><creatorcontrib>Chapman, Jeremy R</creatorcontrib><title>Once-Daily Extended-Release Versus Twice-Daily Standard-Release Tacrolimus in Kidney Transplant Recipients: A Systematic Review</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>BACKGROUNDA simplified dosing regimen may improve drug compliance in kidney transplant recipients and long-term graft outcomes. We aimed to identify, appraise, and synthesize the current evidence comparing the relative safety and efficacy of the recently introduced daily versus standard twice-daily tacrolimus administration.
METHODSWe systematically reviewed all randomized controlled trials and observational studies that compared the outcomes of daily versus twice-daily tacrolimus formulation in kidney transplant recipients. Medline (from 1948 to July week 4 2011), Embase (1980 to 2011 week 31), the Cochrane Library (1991 to June 2011), and conference proceedings were searched without language restriction.
RESULTSSix randomized controlled trials (n=2499) and 15 observational studies (n=2886) were included in the review. There were no significant differences in biopsy-proven acute rejection (two trials, n=1093; risk ratio [RR; confidence interval (CI)], 1.24 [0.93–1.65]; P=0.15; I=0%), patient survival (three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.55; I=32%), and graft survival (three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.67; I=0%) between the two formulations at 12 months. Similar results for acute rejection (five studies, n=391; RR [CI], 0.99 [0.93–1.06]; P=0.84; I=0%) and overall patient survival (two studies, n=218; RR [CI], 1.02 [0.94–1.10]; P=0.62; I=0%) were observed in observational studies.
CONCLUSIONSOnce-daily tacrolimus appears to be as effective as twice-daily tacrolimus up to 12 months after kidney transplantation.</description><subject>Bacterial Infections - epidemiology</subject><subject>Drug Administration Schedule</subject><subject>Graft Rejection</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Kidney Transplantation - mortality</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Tacrolimus - administration & dosage</subject><subject>Tacrolimus - pharmacokinetics</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0UtPxCAQB3BiNLo-PoGJ6dFLFQqU1pvR9RFNNFq9NhSmEaXdFajrnvzqYtZH4sF44sBvZhj-CG0TvEdwKfar6z3cYEKBkiIrmCK8WUIjwilLc1zgZTTCmJGUUCrW0Lr3jxhjToVYRWsZ5SxjeTlCb1e9gvRYGjtPxq8Beg06vQEL0kNyD84PPqlm5tvcBtlr6X5MJZWbWNNFZ_rkwuge5knlZO-nVvYhuQFlpgb64A-Sw-R27gN0MhgVL14MzDbRSiuth63PcwPdnYyro7P08ur0_OjwMlWU5k1cgpV5wdqMcc4bnSutdC6KrClayeJamnFGCOVE6BLKRmGQHBcEa93QtmxzuoF2F32nbvI8gA91Z7wCG98Ik8HXhLE4qCz5PygVOI-Yi0jpgsY_8N5BW0-d6aSb1wTXHyHV1XX9O6RYtfM5YGg60N81X6lEIBZgNrEhZvBkhxm4-gGkDQ9_tn4HMQWgOg</recordid><startdate>20130515</startdate><enddate>20130515</enddate><creator>Ho, Elaine T.L</creator><creator>Wong, Germaine</creator><creator>Craig, Jonathan C</creator><creator>Chapman, Jeremy R</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20130515</creationdate><title>Once-Daily Extended-Release Versus Twice-Daily Standard-Release Tacrolimus in Kidney Transplant Recipients: A Systematic Review</title><author>Ho, Elaine T.L ; Wong, Germaine ; Craig, Jonathan C ; Chapman, Jeremy R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336b-1349684f24555bd6cdcd6782b8fa4005d454113517d9e9bc0ea50810ddb3f9f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Bacterial Infections - epidemiology</topic><topic>Drug Administration Schedule</topic><topic>Graft Rejection</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Kidney Transplantation - mortality</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Tacrolimus - administration & dosage</topic><topic>Tacrolimus - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ho, Elaine T.L</creatorcontrib><creatorcontrib>Wong, Germaine</creatorcontrib><creatorcontrib>Craig, Jonathan C</creatorcontrib><creatorcontrib>Chapman, Jeremy R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ho, Elaine T.L</au><au>Wong, Germaine</au><au>Craig, Jonathan C</au><au>Chapman, Jeremy R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Once-Daily Extended-Release Versus Twice-Daily Standard-Release Tacrolimus in Kidney Transplant Recipients: A Systematic Review</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>2013-05-15</date><risdate>2013</risdate><volume>95</volume><issue>9</issue><spage>1120</spage><epage>1128</epage><pages>1120-1128</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><abstract>BACKGROUNDA simplified dosing regimen may improve drug compliance in kidney transplant recipients and long-term graft outcomes. We aimed to identify, appraise, and synthesize the current evidence comparing the relative safety and efficacy of the recently introduced daily versus standard twice-daily tacrolimus administration.
METHODSWe systematically reviewed all randomized controlled trials and observational studies that compared the outcomes of daily versus twice-daily tacrolimus formulation in kidney transplant recipients. Medline (from 1948 to July week 4 2011), Embase (1980 to 2011 week 31), the Cochrane Library (1991 to June 2011), and conference proceedings were searched without language restriction.
RESULTSSix randomized controlled trials (n=2499) and 15 observational studies (n=2886) were included in the review. There were no significant differences in biopsy-proven acute rejection (two trials, n=1093; risk ratio [RR; confidence interval (CI)], 1.24 [0.93–1.65]; P=0.15; I=0%), patient survival (three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.55; I=32%), and graft survival (three trials, n=1156; RR [CI], 0.99 [0.97–1.02]; P=0.67; I=0%) between the two formulations at 12 months. Similar results for acute rejection (five studies, n=391; RR [CI], 0.99 [0.93–1.06]; P=0.84; I=0%) and overall patient survival (two studies, n=218; RR [CI], 1.02 [0.94–1.10]; P=0.62; I=0%) were observed in observational studies.
CONCLUSIONSOnce-daily tacrolimus appears to be as effective as twice-daily tacrolimus up to 12 months after kidney transplantation.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>23542469</pmid><doi>10.1097/TP.0b013e318284c15b</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1337 |
| ispartof | Transplantation, 2013-05, Vol.95 (9), p.1120-1128 |
| issn | 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1443369956 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Bacterial Infections - epidemiology Drug Administration Schedule Graft Rejection Graft Survival Humans Immunosuppressive Agents - administration & dosage Kidney Transplantation - mortality Randomized Controlled Trials as Topic Tacrolimus - administration & dosage Tacrolimus - pharmacokinetics |
| title | Once-Daily Extended-Release Versus Twice-Daily Standard-Release Tacrolimus in Kidney Transplant Recipients: A Systematic Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T12%3A01%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Once-Daily%20Extended-Release%20Versus%20Twice-Daily%20Standard-Release%20Tacrolimus%20in%20Kidney%20Transplant%20Recipients:%20A%20Systematic%20Review&rft.jtitle=Transplantation&rft.au=Ho,%20Elaine%20T.L&rft.date=2013-05-15&rft.volume=95&rft.issue=9&rft.spage=1120&rft.epage=1128&rft.pages=1120-1128&rft.issn=0041-1337&rft.eissn=1534-6080&rft_id=info:doi/10.1097/TP.0b013e318284c15b&rft_dat=%3Cproquest_cross%3E1443369956%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1370633657&rft_id=info:pmid/23542469&rfr_iscdi=true |